June 2018

New Product - Mavenclad

Cladribine (Mavenclad) is a nucleoside analogue of deoxyadenosine. The mechanism by which cladribine exerts its therapeutic effects in multiple sclerosis (MS) is not fully elucidated but its predominant effect on B and T lymphocytes is thought to interrupt the cascade of immune events central to MS. Mavenclad is indicated for the treatment of relapsing-remitting MS to reduce the frequency of clinical relapses and to delay the progression of physical disability. Following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4. Re-initiation of therapy after year 4 has not been studied. Mavenclad is contraindicated with: human immunodeficiency virus infection; active chronic infections (tuberculosis, hepatitis); immunocompromise, including patients receiving immunosuppressive or myelosuppressive therapy with agents such as ciclosporin, methotrexate, mitoxantrone, azathioprine, natalizumab, or chronic use of corticosteroids (acute short-term therapy with corticosteroids can be administered); moderate or severe renal impairment (creatinine clearance < 60 mL/min); pregnancy and breastfeeding. Mavenclad 10 mg tablets are available in a pack size of 1, 4 and 6.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629